David has more than 40 years of experience in various leadership roles within the ophthalmic pharmaceutical industry and is currently the Board Chairman of Oxular and a Board member of the Glaucoma Foundation. He was previously CEO of Nightstar Therapeutics, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies with David leading the company through a successful NASDAQ listing and M&A transaction. He was previously Vice President of Johnson & Johnson’s Vision Care Franchise, and, prior to that, held several roles at Allergan for 25 years, including Regional President. Mr. Fellows holds a B.A. in Psychology from Butler University.